The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Gerald L. DeNardo

University of California

Davis Medical Center


CA 95816



Name/email consistency: high



  • University of California, Davis Medical Center, Sacramento, CA 95816, USA. 1998 - 2010
  • Department of Internal Medicine, University of California, Davis, Sacramento, USA. 2008
  • Radiodiagnosis and Therapy Molecular Cancer Institute, Sacramento, CA 95816, USA. 2000 - 2007
  • Radiodiagnosis and Therapy, University of California Davis Medical Center, 1508 Alhambra Boulevard #3100, Sacramento, USA. 2005
  • Department of Internal Medicine, Division of Hematology and Oncology, Section of Radiodiagnosis and Therapy, University of California, USA. 2002


  1. Dose intensified molecular targeted radiotherapy for cancer-lymphoma as a paradigm. DeNardo, G., DeNardo, S. Semin. Nucl. Med (2010) [Pubmed]
  2. Molecular specific and cell selective cytotoxicity induced by a novel synthetic HLA-DR antibody mimic for lymphoma and leukemia. DeNardo, G.L., Mirick, G.R., Hok, S., DeNardo, S.J., Beckett, L.A., Adamson, G.N., Balhorn, R.L. Int. J. Oncol. (2009) [Pubmed]
  3. Systemic radiotherapy can cure lymphoma: a paradigm for other malignancies? DeNardo, G.L., DeNardo, S.J., Balhorn, R. Cancer Biother. Radiopharm. (2008) [Pubmed]
  4. Nanomolecular HLA-DR10 antibody mimics: A potent system for molecular targeted therapy and imaging. DeNardo, G.L., Natarajan, A., Hok, S., Mirick, G., DeNardo, S.J., Corzett, M., Sysko, V., Lehmann, J., Beckett, L., Balhorn, R. Cancer Biother. Radiopharm. (2008) [Pubmed]
  5. Pharmacokinetic characterization in xenografted mice of a series of first-generation mimics for HLA-DR antibody, Lym-1, as carrier molecules to image and treat lymphoma. DeNardo, G.L., Natarajan, A., Hok, S., Perkins, J., Cosman, M., DeNardo, S.J., Lightstone, F.C., Mirick, G.R., Miers, L.A., Balhorn, R.L. J. Nucl. Med. (2007) [Pubmed]
  6. Characteristics of dimeric (bis) bidentate selective high affinity ligands as HLA-DR10 beta antibody mimics targeting non-Hodgkin's lymphoma. DeNardo, G.L., Hok, S., Van Natarajan, A., Cosman, M., DeNardo, S.J., Lightstone, F.C., Mirick, G.R., Yuan, A., Perkins, J., Sysko, V.V., Lehmann, J., Balhorn, R.L. Int. J. Oncol. (2007) [Pubmed]
  7. Cure of incurable lymphoma. DeNardo, G.L., Sysko, V.V., DeNardo, S.J. Int. J. Radiat. Oncol. Biol. Phys. (2006) [Pubmed]
  8. Concepts in radioimmunotherapy and immunotherapy: Radioimmunotherapy from a Lym-1 perspective. DeNardo, G.L. Semin. Oncol. (2005) [Pubmed]
  9. Treatment of non-Hodgkin's lymphoma (NHL) with radiolabeled antibodies (mAbs). DeNardo, G.L. Semin. Nucl. Med (2005) [Pubmed]
  10. Direct antilymphoma effects on human lymphoma cells of monotherapy and combination therapy with CD20 and HLA-DR antibodies and 90Y-labeled HLA-DR antibodies. DeNardo, G.L., Tobin, E., Chan, K., Bradt, B.M., DeNardo, S.J. Clin. Cancer Res. (2005) [Pubmed]
  11. Evaluation of a cathepsin-cleavable peptide linked radioimmunoconjugate of a panadenocarcinoma MAb, m170, in mice and patients. DeNardo, G.L., DeNardo, S.J. Cancer Biother. Radiopharm. (2004) [Pubmed]
  12. Radiometals as payloads for radioimmunotherapy for lymphoma. DeNardo, G.L., Kennel, S.J., Siegel, J.A., Denardo, S.J. Clin. Lymphoma (2004) [Pubmed]
  13. Human antiglobulin response to foreign antibodies: therapeutic benefit?. DeNardo, G.L., Bradt, B.M., Mirick, G.R., DeNardo, S.J. Cancer Immunol. Immunother. (2003) [Pubmed]
  14. Impact of interpatient pharmacokinetic variability on design considerations for therapy with radiolabeled MAbs. DeNardo, G., Yuan, A., Goldstein, D., Richman, C., O'Donnell, R., Shen, S., Hartmann Siantar, C., DeNardo, S. Cancer Biother. Radiopharm. (2003) [Pubmed]
  15. Characterization of human IgG antimouse antibody in patients with B-cell malignancies. DeNardo, G.L., Mirick, G.R., Kroger, L.A., Bradt, B.M., Lamborn, K.R., DeNardo, S.J. Clin. Cancer Res. (2003) [Pubmed]
  16. Rationales, evidence, and design considerations for fractionated radioimmunotherapy. DeNardo, G.L., Schlom, J., Buchsbaum, D.J., Meredith, R.F., O'Donoghue, J.A., Sgouros, G., Humm, J.L., DeNardo, S.J. Cancer (2002) [Pubmed]
  17. Radiation dosimetry for radionuclide therapy in a nonmyeloablative strategy. DeNardo, G.L., Siantar, C.L., DeNardo, S.J. Cancer Biother. Radiopharm. (2002) [Pubmed]
  18. Role of radiation dosimetry in radioimmunotherapy planning and treatment dosing. DeNardo, G.L., Juweid, M.E., White, C.A., Wiseman, G.A., DeNardo, S.J. Crit. Rev. Oncol. Hematol. (2001) [Pubmed]
  19. 131I-Lym-1 in mice implanted with human Burkitt's lymphoma (Raji) tumors: loss of tumor specificity due to radiolysis. DeNardo, G.L., DeNardo, S.J., Wessels, B.W., Kukis, D.L., Miyao, N., Yuan, A. Cancer Biother. Radiopharm. (2000) [Pubmed]
  20. Are radiometal-labeled antibodies better than iodine-131-labeled antibodies: comparative pharmacokinetics and dosimetry of copper-67-, iodine-131-, and yttrium-90-labeled Lym-1 antibody in patients with non-Hodgkin's lymphoma. DeNardo, G.L., DeNardo, S.J., O'Donnell, R.T., Kroger, L.A., Kukis, D.L., Meares, C.F., Goldstein, D.S., Shen, S. Clin. Lymphoma (2000) [Pubmed]
  21. Maximum-tolerated dose, toxicity, and efficacy of (131)I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma. DeNardo, G.L., DeNardo, S.J., Goldstein, D.S., Kroger, L.A., Lamborn, K.R., Levy, N.B., McGahan, J.P., Salako, Q., Shen, S., Lewis, J.P. J. Clin. Oncol. (1998) [Pubmed]
WikiGenes - Universities